Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Pan-Cancer Therapeutics and ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CEACAM6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CEACAM6 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View CEACAM6 Products |
| Gene Delivery | CEACAM6 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation (flow cytometry & internalization assays). |
View CEACAM6 Products |
| Benchmark Ab | Anti-CEACAM6 Recombinant Antibody (Sequence of BAY2701439) Recombinant positive control for functional benchmark assays. |
View CEACAM6 Products |
| Validator | CEACAM6 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View CEACAM6 Products |
| Related Target A | CEACAM5 High-homology family member. Crucial for cross-reactivity and selectivity screening in ADC/mAb discovery. |
View CEACAM5 Products |
| Related Target B | CEACAM1 Inhibitory receptor on immune cells. Counter-screening is required to prevent off-target immune suppression. |
View CEACAM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-family selectivity (CEACAM1, 3, 5, 8) | A complete panel of recombinant CEACAM family proteins, sequence-verified and expressed in HEK293. |
| ADC internalization assessment | HEK293-expressed CEACAM6 with native post-translational modifications (PTMs) to ensure physiological epitope presentation. |
| Lack of clinical-grade positive controls | Sequence-verified clinical biosimilar antibodies (e.g., BAY2701439 sequence) for assay calibration. |
| Target expression variability in cell lines | Lentiviral vectors for stable, high-level CEACAM6 expression to standardize cell-based assays. |
Live CEACAM6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CEACAM6 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to Antibody-Drug Conjugates (ADCs) and bispecific T-cell engagers (BiTEs). Because CEACAM6 is overexpressed in a wide range of solid tumors—including pancreatic, non-small cell lung (NSCLC), and colorectal cancers—while showing restricted expression in normal tissues, it represents a highly viable tumor-associated antigen (TAA).
As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective epitopes. The primary challenge is avoiding off-target binding to CEACAM1 (expressed on immune cells) and CEACAM8 (expressed on granulocytes), which can lead to neutropenia or immune evasion. Consequently, developers require highly precise, structurally intact recombinant proteins to screen out cross-reactive clones during the early discovery phase.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Bayer, Sanofi (related CEACAM programs) | Pancreatic Cancer, NSCLC, Breast Cancer | Internalization Assay & Endocytosis kinetics (Requires native glycosylated CEACAM6 protein) |
| Bispecific / BiTE | Academic institutions, Biotech startups | Gastrointestinal Cancers, Solid Tumors | Affinity profiling on target vs. off-target family members (Requires CEACAM1/5/6/8 panel) |
| Monoclonal Antibody | Various oncology-focused biopharma | Colorectal Cancer, Hematological malignancies | Epitope mapping and cross-species reactivity (Requires Human vs. Cynomolgus CEACAM6) |